TWD 91.2
(0.0%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 801.77 Million TWD | 14.31% |
2022 | 701.43 Million TWD | 10.22% |
2021 | 636.41 Million TWD | -3.41% |
2020 | 658.86 Million TWD | 7.28% |
2019 | 614.15 Million TWD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 831.21 Million TWD | 3.67% |
2024 Q2 | 831.21 Million TWD | 0.0% |
2023 Q3 | 801.77 Million TWD | -7.56% |
2023 Q4 | 801.77 Million TWD | 0.0% |
2023 FY | 801.77 Million TWD | 14.31% |
2023 Q2 | 867.36 Million TWD | 0.0% |
2023 Q1 | 867.36 Million TWD | 23.66% |
2022 Q3 | 701.43 Million TWD | 0.0% |
2022 Q4 | 701.43 Million TWD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Allied Biotech Corporation | 2.07 Billion TWD | 61.433% |
GeneFerm Biotechnology Co., Ltd. | 1.17 Billion TWD | 31.786% |
Easywell Biomedicals, Inc. | 1.21 Billion TWD | 33.944% |
TTY Biopharm Company Limited | 9.87 Billion TWD | 91.881% |
Synmosa Biopharma Corporation | 11.72 Billion TWD | 93.164% |
Orient EuroPharma Co., Ltd. | 10.81 Billion TWD | 92.584% |
Center Laboratories, Inc. | 27 Billion TWD | 97.031% |
Tien Liang BioTech Co., Ltd. | 654.03 Million TWD | -22.589% |
Orient Pharma Co., Ltd. | 2.56 Billion TWD | 68.713% |
InnoPharmax Inc. | 524.19 Million TWD | -52.953% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 1.99 Billion TWD | 59.769% |
Excelsior Biopharma Inc. | 1.57 Billion TWD | 49.169% |
DV Biomed Co., Ltd. | 1.81 Billion TWD | 55.768% |
Foresee Pharmaceuticals Co., Ltd. | 1.86 Billion TWD | 56.927% |
Handa Pharmaceuticals, Inc. | 3.03 Billion TWD | 73.601% |
UniPharma Co., Ltd. | 350.07 Million TWD | -129.03% |
Anxo Pharmaceutical Co., Ltd. | 2.21 Billion TWD | 63.861% |
Alar Pharmaceuticals Inc. | 973.2 Million TWD | 17.615% |
Mercury Biopharmaceutical Corporation | 438.07 Million TWD | -83.023% |
Bioray Biotech Co., Ltd | 542.64 Million TWD | -47.753% |
TSH Biopharm Corporation Limited | 1.39 Billion TWD | 42.725% |